Compare MBBC & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | CVM |
|---|---|---|
| Founded | 1902 | 1983 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 32.4M |
| IPO Year | N/A | 1996 |
| Metric | MBBC | CVM |
|---|---|---|
| Price | $13.76 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 57.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $9.94 | $0.23 |
| 52 Week High | $14.64 | $13.48 |
| Indicator | MBBC | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 37.82 |
| Support Level | $12.93 | $3.18 |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 0.41 | 0.36 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 99.47 | 2.50 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.